Long-term Effects of Indirect Hyperbilirubinemia on Auditory and Neurological Functions in Term Newborns

Term Yenidoğanlarda İndirekt Hiperbilirubineminin İşitsel ve Nörolojik Fonksiyonlar Üzerine Uzun Dönem Etkileri

Gulser Esen BESLI®, Fazilet METIN®, Mehmet Ateş AKSIT®, Sema SALTİK®

ABSTRACT
Objective: The aim of this study was to investigate the long-term effects of hyperbilirubinemia on neurological and hearing function in otherwise healthy term newborns with neonatal indirect hyperbilirubinemia.
Method: This study was performed prospectively in 41 term newborns hospitalized for indirect hyperbilirubinemia. Patients with no signs of hemolysis were categorized in 3 groups based on stabil levels as sTB <20 mg/dl, 20-24.9 mg/dl, and >25 mg/dl. Patients with total bilirubin level >20 mg/dl and hemolytic disease classified as the fourth group. The relationship between maximum sTB level, duration of exposure to sTB levels >20 mg/dl and etiology of jaundice with neurological and auditory functions was investigated. Detailed neurological examination, Denver II developmental screening test and hearing tests (otoacoustic emissions, OAE and auditory brainstem responses, ABR) were performed to all patients between 18-24 months of age.
Results: Neurodevelopmental disorder was found in 5 (12.2%) patients. Hemolytic disease was detected in two of these patients. Hearing loss was found in 4 (9.8%) patients. Two of these patients had auditory neuropathy spectrum disorder and the other two had cochlear hearing loss. The sTB levels of all these patients were above 25 mg/dl. No neurological disorder or hearing loss was found in the patients who had stabil of <25 mg/dl. Exposure time to sTB levels above 20 mg/dl was significantly longer in patients with neurological dysfunction and pathologic ABR results (p<0.007, p<0.007; p<0.05).
Conclusion: This study demonstrates that kernicterus may develop in term newborns with severe hyperbilirubinemia (sTB>25 mg/dl) without any finding of significant hemolysis. Not only the bilirubin level but also the duration of exposure to high bilirubin levels may be effective in the development of bilirubin neurotoxicity. The high rate of hearing loss in our patients emphasizes the importance of screening for infants with severe hyperbilirubinemia using comprehensive auditory evaluation for early diagnosis of possible hearing loss.
Keywords: Term neonates, hyperbilirubinemia, neurotoxicity, auditory neuropathy, auditory brainstem responses

ÖZ
Amaç: Bu çalışmada, neonatal indirekt hiperbilirubinemi dışında başka sorunu olmayan term yenidoganlarda, hiperbilirubineminin nörolojik gelişim ve işitsel fonksiyonlara üzerinde uzun dönem etkilerinin araştırılması amaçlanmıştır.
Yëntem: Bu çalışma, indirekt hiperbilirubinemi nedeniyle yatırılan tedavi edilen 41 term yenidoganın 18-24 aylık dönemlerinde işitsel ve nörolojik fonksiyonların değerlendirilmesi amaçlanmıştır. Tüm hastaların 18-24 aylık dönemde sinir ve işitsel fonksiyonlar değerlendirildi. Çalışmada 5 (12.2%) hastada nörolojik bozukluk saptandı. Hemolitik bozukluk 2 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi. İşitsel bozukluk 4 hastada tespit edildi....

Anasatır kelime: Term yenidogan, hiperbilirubinemi, nörotoxikisite, işitsel nöropati, işitsel beyin sapı cevaplar
INTRODUCTION

Neonatal indirect hyperbilirubinemia is one of the most common problems of the newborn period and has mostly a benign course. The risk of neurotoxicity due to severe neonatal hyperbilirubinemia has been known for many years\(^1\). Since the early 1990s, it has been shown that the risk of kernicterus is much lower in healthy, term infants who have not hemolysis compared to those who have. and serum total bilirubin (sTB) limits have been drawn up in the treatment of these infants. However, kernicterus has been increasingly reported in healthy, predominantly breastfed term and near-term newborns with hyperbilirubinemia in the years following the application of more moderate treatment approaches\(^2\). The most important factors that increase the risk of bilirubin neurotoxicity include isoimmune hemolytic disease, glucose-6-phosphate dehydrogenase deficiency, prematurity, low birth weight, hypercarbia, sepsis, acidosis, asphyxia and hypoalbuminemia. Infants with these risk factors may develop severe hyperbilirubinemia despite appropriate monitoring and treatment\(^1,3,4\). Therefore, treatment guidelines for newborns with hyperbilirubinemia have been updated since 2004. The limits of phototherapy and exchange transfusion were re-determined using the bilirubin nomograms, which were established according to sTB levels, gestational age, postnatal age, risk factors, and duration of postnatal period in hours\(^3,5,6\). Nevertheless, severe hyperbilirubinemia and bilirubin toxicity may develop in term, breast-fed infants who do not suffer from hemolytic disease. It is not clear how and how often many newborns with similar bilirubin levels are protected from bilirubin toxicity\(^1,2,4\). It is thought that some unknown stressors and genetic predisposition may increase the risk of toxicity\(^5,7\). The effect of exposure to high bilirubin levels on the development of kernicterus is also unknown\(^1\).

Today, although less often, bilirubin encephalopathy and kernicterus continue to be clinical conditions that are still encountered in Turkey and all over the world. Kernicterus is one of the major causes of cerebral palsy, hearing loss, and developmental disorders in children\(^3,6\). While kernicterus may develop later in infants with hyperbilirubinemia who have no signs of acute bilirubin encephalopathy during the neonatal period, the prognosis of patients in whom development of bilirubin toxicity is suspected can only be determined during long-term follow-up\(^4,7\). Therefore, long-term follow-up of infants with hyperbilirubinemia in terms of bilirubin toxicity is of great importance for early detection and treatment of possible disorders.

The aim of this study was to investigate the long-term effects of hyperbilirubinemia in term neonates with regard to auditory functions and neurological development, and to investigate the relationship between sTB levels and duration of exposure to high bilirubin levels with auditory and neurological dysfunction.

MATERIALS and METHODS

The study was approved by the local Ethics Committee (Date: 12.01.1999, Number: 1999/028). Informed consent was taken from the parents of the patients enrolled in this study.

Study Population and Setting

The study was conducted prospectively on 41 out of 207 patients with the diagnosis of hyperbilirubinemia who were hospitalized at a tertiary care hospital and met the inclusion criteria within a period of six months. Inclusion criteria were as follows: gestational age, ≥ 37 weeks, birth weight, ≥2500 g; sTB levels above physiological limits; absence of: asphyxia, birth trauma, metabolic disorders (hypoglycemia, hypocalcemia, acidosis, electrolyte disorder and hypoalbuminemia); neonatal infections (sepsis, meningitis and pneumonia); intrauterine infection, congenital metabolic disease, congenital anomaly, pathologies that may lead to neonatal cerebral damage such as intracranial hemorrhage;
and family history of hearing loss, and suitability for long term follow-up (Figure 1). Family consent was obtained for all the cases. In order to compare the hearing test results, a control group consisting of 12 children between 18-24 months of age with no risk factors for neurological development and hearing loss, especially jaundice, was formed.

A jaundice follow-up form was formulated and the antenatal and natal characteristics, the day when jaundice was noticed, the first feeding time, feeding type and frequency, time to meconium passage, physical examination findings at the time of admission, laboratory tests, treatment method and duration, and etiology of jaundice were recorded for all cases. Maternal and infant blood groups, direct Coombs test, complete blood count, reticulocyte count, and quantitative glucose-6-phosphate dehydrogenase enzyme measurements were performed in all infants. Blood smear was stained with May-Gruenwald-Giemsa dye and erythrocyte morphology was evaluated. Serum total bilirubin measurements were performed by spectrophotometric method and were followed at 4 hours intervals unless more frequent measurements were required. The presence of jaundice within the first 24 hours, low hematocrit value, reticulocytosis, direct Coombs test positivity, and erythrocyte morphology supporting hemolysis suggested the diagnosis of hemolytic disease.

The study group was divided into 4 groups based on the presence of maximum sTB and hemolysis. Patients without any signs of hemolysis and unidentified jaundice etiology were grouped based on sTB levels as sTB <20 mg/dl (Group I), 20-24.9 mg/dl (Group II), and ≥25 mg/dl (Group III). Patients with total bilirubin level of ≥20 mg/dl and hemolytic disease were identified as Group IV. In the study group, all cases underwent detailed neurological examinations between postnatal 18-24th months (mean 21.02±1.67 months) by a pediatric neurologist. Furthermore, Denver II developmental screening test, auditory brainstem responses (ABRs) and otoacoustic emission tests (OAEs) were performed. Prior to evaluation process using ABR and OAE tests, all subjects were examined by an otorhinolaryngologist to exclude possible middle ear pathologies. Impedance audiometry test was performed in patients as recommended by the otorhinolaryngologist and in patients with pathological OAE/ABR test results. Cranial magnetic resonance imaging (MRI) was performed to show the neuroanatomic localization of bilirubin toxicity in cases with pathological ABR results and/or neurological findings.

**Measurements**

Evaluation of Hearing acuity (ABR, OAE and tympanometry) was performed in the soundproof room at an Audiological Diagnostic Center. All audiological assessments and interpretations were done by an audiologist (Ph.D). Danplex-TYMP-87-Clinical-Middle-Ear-Analyzer was used for impedance audiometry test. Auditory Brainstem responses were recorded by Amplaid MK12 electrophysiological measuring instrument. Silver electrodes were placed at the midline scalp border (as positive), ipsilateral earlobe (as negative) and between two eyebrows (as ground). Electrode impedances were not allowed to exceed 5 Kohm. Recordings were obtained monaurally using 100 microsecond click acoustic stimuli. The stimuli were delivered.
through TDH 49 headphones. In the diagnostic test, recurrent 1000 stimuli in alternate polarity with 11/sec rate at 70 dBnHL intensity were used. If wave V was not seen clearly, test was repeated with rarefaction/condensation polarity at the same intensity level to record cochlear microphonics. If wave V was recorded clearly then level of 60 and 30 dB nHL were also controlled with 21/sec rate stimulus. Each condition was recorded with double traces.

Otoacoustic emissions were obtained by “transient evoked otoacoustic emission, TEOAE” technique. The test was performed using Otodynamics’ ILO 96 (version 5) equipment. In the Quickscreen mode, 80 dB pe SPL click stimulus was applied in a 2.5-12.5 ms time window (±6). The stimulus frequency was 80/sec and a total of 260 click stimuli were used. The test results were evaluated as “passed” and “failed”. Signal-to-noise ratio of 3 dB or higher in at least 3 of the 0.8 kHz, 1.6 kHz, 2.4 kHz, 3.2 kHz and 4.0 kHz frequency bands was considered as “passed”.

The Denver II Developmental Screening Test was applied to all subjects by the Denver II Developmental Screening Test certified researcher. Test results were evaluated as “normal, suspicious, abnormal” and the suspicious tests were repeated 3 months later.

**Statistical Analyses**

ABR I, III, V absolute wave latencies and interpeak intervals of I-III, III-V and I-V waves between the study and the control groups were compared. The relationship between maximum sTB level and duration of exposure to sTB levels above 20 mg/dl with neurological dysfunction and ABR results was investigated.

SPSS (Statistical Package for Social Sciences) for Windows 7.0 was used for statistical analysis. Oneway Anova, Kruskal Wallis Test, Mann Whitney U test and Spearman correlation analysis were used for the comparison of quantitative data as well as descriptive statistical methods (mean, standard deviation). The Fisher Exact chi-square test was used to compare the qualitative data. Results were evaluated at 95% confidence interval and p<0.05 level of significance.

**RESULTS**

Of the 41 patients recruited for the study, 23 (56%) were male and 18 (44%) were female, with a mean age of 21.02±1.67 months. Characteristics of the patients according to the study subgroups (gestational age, birth weight, day of hospitalization, sTB level, hematocrit, reticulocyte values, current age) are shown in Table 1. ABR audiometry revealed that I, III, V wave absolute latencies and interpeak intervals of I-III, III-V, and I-V waves were not significantly different between the study and the control groups (Table 2). Hearing problem was found in 4 (9.8%) of 41 patients and Denver II test was evaluated as abnormal in 5 (12.2%) patients. Various neurological findings were found in all of these patients. All of the patients with neurological disorder and hearing problems were in Groups III and IV, and they were referred to our hospital from rural areas. All of the cases with pathological OAE/ABR results passed the tympanometric test. Static compliances were between 0.22 and 0.56 cc. Relevant detailed data are presented in Table 3. Infants in Groups I and II had no neurological dysfunction or hearing problem (no hemolysis and sTB<25 mg/dl). There was a significant relationship between the presence of neurological findings and the pathological ABR results (p<0.001, Table 4). The maximum sTB of the patients with neurological dysfunction and ABR pathology was found to be significantly higher than the other patients (p:0.001 and 0.002, respectively; Table 5). Similarly, in patients with neurological dysfunction and pathologic ABR findings, duration of exposure to sTB levels above 20 mg/dl was significantly longer than the other patients (p:0.007 and 0.007, respectively; Table 6).
Table 1. Characteristics of the patients by groups.

|                          | Group | Number of Patients (n) | Mean±Standard Deviation |
|--------------------------|-------|------------------------|-------------------------|
| Gestational age (weeks)  | I     | 11                     | 39.91±1.30              |
|                          | II    | 10                     | 39.40±1.08              |
|                          | III   | 10                     | 38.90±1.60              |
|                          | IV    | 10                     | 40.10±0.88              |
|                          | Total | 41                     | 39.59±1.28              |
| Birth weight (grams)     | I     | 11                     | 3372.90±541.00          |
|                          | II    | 10                     | 3255.00±559.99          |
|                          | III   | 10                     | 3115.00±274.92          |
|                          | IV    | 10                     | 3124.50±360.87          |
|                          | Total | 41                     | 3220.60±449.21          |
| Day of hospitalization   | I     | 11                     | 6.27±3.90               |
|                          | II    | 10                     | 5.00±2.62               |
|                          | III   | 10                     | 6.60±1.43               |
|                          | IV    | 10                     | 6.00±5.19               |
|                          | Total | 41                     | 5.98±4.50               |
| Maximum TB* level (mg/dl)| I     | 11                     | 18.23±1.11              |
|                          | II    | 10                     | 22.91±0.59              |
|                          | III   | 10                     | 30.92±7.94              |
|                          | IV    | 10                     | 31.69±6.70              |
|                          | Total | 41                     | 25.75±7.60              |
| TB* > 20 mg/dl duration (hours) | I | - | - |
|                          | II    | 10                     | 7.95±4.42               |
|                          | III   | 10                     | 16.15±5.61              |
|                          | IV    | 10                     | 14.75±7.32              |
|                          | Total | 30                     | 12.95±6.76              |
| Hematocrit (%)           | I     | 11                     | 56.27±5.48              |
|                          | II    | 10                     | 52.60±4.62              |
|                          | III   | 10                     | 55.93±9.36              |
|                          | IV    | 10                     | 49.80±8.42              |
|                          | Total | 41                     | 53.71±7.43              |
| Reticulocytes (%)        | I     | 11                     | 1.28±0.65               |
|                          | II    | 10                     | 2.21±1.48               |
|                          | III   | 10                     | 1.64±0.78               |
|                          | IV    | 10                     | 7.25±1.13               |
|                          | Total | 41                     | 3.05±2.64               |
| Current age of the patients (months) | I | 11 | 21.64±1.47 |
|                          | II    | 10                     | 21.95±1.54              |
|                          | III   | 10                     | 20.60±1.71              |
|                          | IV    | 10                     | 19.85±1.23              |
|                          | Total | 41                     | 21.02±1.67              |

*TB= Total bilirubin

Table 2. Comparison of Auditory Brainstem Response Wave Latencies (ms) and Interpeak Intervals (ms) Between the Study and Control Groups.

|                           | Group I n=11 | Group II n=10 | Group III n=8 | Group IV n=8 | Controls n=12 | p       |
|---------------------------|--------------|--------------|--------------|--------------|---------------|---------|
| Wave I Latency            | 1.68±0.07    | 1.68±0.10    | 1.69±0.13    | 1.72±0.16    | 1.63±0.08     | 0.698   |
| Wave III Latency          | 3.89±0.16    | 3.93±0.09    | 3.93±0.15    | 3.96±0.12    | 3.93±0.10     | 0.883   |
| Wave V Latency            | 5.81±0.12    | 5.81±0.08    | 5.83±0.09    | 5.80±0.19    | 5.73±0.16     | 0.455   |
| I-III Interpeak interval  | 2.20±0.14    | 2.25±0.09    | 2.23±0.15    | 2.24±0.15    | 2.29±0.09     | 0.584   |
| I-V Interpeak interval    | 4.13±0.10    | 4.12±0.14    | 4.14±0.09    | 4.08±0.19    | 4.10±0.14     | 0.876   |
| III-V Interpeak interval  | 1.92±0.13    | 1.87±0.08    | 1.91±0.13    | 1.83±0.11    | 1.80±0.15     | 0.195   |
| Case | Group | Maximum sTBI level (mg/dL) | Duration of exposure to sTBI levels > 20 mg/dL (hours) | Treatment | Neurologic assessment | Denver II Test | Cranial MRI | OAE | ABR |
|------|-------|---------------------------|---------------------------------|-----------|----------------------|---------------|-------------|-----|-----|
| 1    | III   | 37.2                      | 24                              | PT+ET (Twice) | Moderate to severe psychomotor retardation, limitation of vertical eye movements, hipotonia. | Abnormal (Chronological age: 18 months. Developmental age: personal-social, language and gross motor 8-9 months, fine motor 11-12 months) | Bilateral symmetrical increased intensity in T2 section of globus pallidus and subtalamic nuclei | Bilateral passed | No waveforms were recorded, cochlear microphonics were obtained (auditory neuropathy spectrum disorder) |
| 2    | III   | 51                         | 20.5                            | PT+ET (Twice) | Severe motor and moderate psychosocial retardation, spasticity, choreoatatic cerebral palsy | Abnormal (Chronological age: 20 months. Developmental age: personal-social, language and motor development 2-3 months) | Cerebral atrophy | Bilateral failed | Wave V at 90 dBnHL (maximum intensity) level was not observed in the left ear. Wave V was normal up to 60 dBnHL in the right ear, and lower levels could not be recorded (bilateral cochlear hearing loss). |
| 3    | III   | 29.7                       | 16                              | PT+ET (Once) | Mild psychosocial motor retardation | Abnormal (Chronological age: 21 months. Developmental age: language 12-13 months, personal-social and gross motor 14-15 months, fine motor 18-19 months) | Normal | Bilateral passed | Bilateral normal recording was obtained. |
| 4    | IV    | 44.6                       | 29.5                            | PT+ET (Thrice) | Mild psychosocial motor retardation | Abnormal (Chronological age: 20 months. Developmental age: language 11-12 months, personal-social and gross motor 14-15 months, fine motor 18-19 months) | Normal | Bilateral failed | Wave V was normal up to 70 dBnHL in the right ear, and lower levels could not be recorded. Wave was normal up to 60 dBnHL in the left ear, and lower levels could not be recorded (bilateral cochlear hearing loss). |
| 5    | IV    | 33.9                       | 16                              | PT+ET (Once) | Mild psychosocial motor retardation, minimal spasticity | Abnormal (Chronological age: 18 months. Developmental age: language 7-8 months, personal-social and gross motor 11-12 months, fine motor 18 months) | Bilateral symmetrical increased intensity in T2 section of bilateral globus pallidus | Bilateral failed (nasal congestion and adenoid vegetation) | No waveforms were recorded, cochlear microphonics were obtained (auditory neuropathy spectrum disorder) |

sTBI: serum total bilirubin, PT: phototherapy, ET: exchange transfusion, MRI: magnetic resonance imaging, OAE: otoacoustic emission, ABR: auditory brainstem response.
DISCUSSION

Indirect hyperbilirubinemia is one of the most common problems in the neonatal period and manifests a broad spectrum ranging from a completely harmless physiological process to severe neurotoxicity and brain damage. The first systematic relationship between bilirubin level and neurotoxicity was reported in the early 1950s, and it was shown that the risk of kernicterus increases with the increase in bilirubin levels in infants with hemolytic disease. Ozmert et al. reported 102 cases with a history of hyperbilirubinemia and aged between 8 and 13 years, and the most prominent kernicterus findings were reported in hemolytic cases with a positive Coombs test. In our study, kernicterus findings were found in five patients (12.2%). While two of these patients (cases 4 and 5) had severe hyperbilirubinemia with hemolytic disease, the others (cases 1, 2 and 3) had no significant hemolysis findings with sTB levels of ≥25 mg/dl. These findings support the opinion that bilirubin neurotoxicity can develop not only in infants with hemolytic disease but also in healthy, term infants without any significant finding of hemolysis and sTB levels above 25 mg/dl. The exact cause of severe hyperbilirubinemia and kernicterus is not known in healthy, term infants without any significant findings of hemolysis. However, severe hyperbilirubinemia is thought to be associated with factors such as early discharge of infants, increase in the risk of dehydration and weight loss due to insufficiently informed mother and breastfeeding problems despite the increase in breast milk feeding frequencies, racial characteristics and genetic predisposition. On the other hand, it can be misleading to decide whether a baby with jaundice has hemolysis based on routine laboratory methods. A case of kernicterus with no signs of hemolysis other than reticulocytosis has been reported. Anna et al. found no signs of hemolysis except mildly low hematocrit values in a case of severe hyperbilirubinemia and kernicterus due to sepsis. In our study, although there was no evidence supporting hemolysis in a case with kernicterus (Case 1), the initial hematocrit value at admission to the hospital was 32.3%, suggesting that a hemolytic process might occur.

### Table 4. Relationship Between Neurological Dysfunction and ABR Results.

| Neurological Dysfunction | Normal | Pathological | Total | P* |
|--------------------------|--------|--------------|-------|----|
| None                     | 36 (87.8%) | 0 (0%)      | 36 (87.8%) |  |
| Present                  | 1 (2.4%)  | 4 (9.8%)    | 5 (12.2%)  | 0.001 |
| Total                    | 37 (90.2%) | 4 (9.8%)    | 41 (100%)  |  |

*p<0.001. ABR; auditory brainstem response

### Table 5. Association Between Maximum sTB Level, ABR Results and Neurological Dysfunction.

| Definition | Maximum sTB Level (mg/dl) | N of patients | P* |
|------------|---------------------------|---------------|----|
| ABR        | Normal                    | 24.03±5.29    | 37 | 0.002 |
|            | Pathological              | 41.68±7.66    | 4  |  |
| Neurological Dysfunction | Present | 23.87±5.28 | 36 | 0.001 |
|            | Present                   | 39.3±8.52     | 5  |  |

*p<0.01. sTB; serum total bilirubin. ABR; auditory brainstem response

### Table 6. Association Between Duration of Exposure to sTB Levels Above 20 mg/dl and Neurological Dysfunction and ABR Results.

| Definition | Number of Cases (n) | Duration of Exposure to sTB Levels Above 20 mg/dl Mean (Hours) ± Std. Deviation | P* |
|------------|--------------------|--------------------------------------------------------------------------------|----|
| ABR Result | Normal             | 11.48±5.68                                                                  | 0.007 |
|            | Pathological       | 22.50±5.70                                                                  |  |
| Neurological Dysfunction | None | 11.30±5.72 |  |
|            | Present            | 21.20±5.72                                                                  | 0.007 |

*p<0.01. sTB; serum total bilirubin, ABR; auditory brainstem response
which could not be detected by other routine laboratory methods.

To prevent the development of severe hyperbilirubinemia and neurotoxicity after hospital discharge, it is important to establish the sTB percentile values and risk factors for all newborns before they are discharged from the hospital, to monitor them according to risk assessment protocols and to follow the current treatment guidelines\(^3,6\). However, it is difficult to implement these current treatment guidelines especially in rural areas with low socioeconomic level, where cases with kernicterus are more frequently seen\(^6\). Therefore, neonatal hyperbilirubinemia remains an important problem with high morbidity and mortality risks, especially in developing countries.

Bilateral sensorineural hearing loss developed at high frequencies has been widely described due to chronic bilirubin encephalopathy. Towards the end of the 1970s, electrophysiological tests such as ABR and OAE have been used to better evaluate cochlear hair cells, 8\(^{th}\) nerve and brainstem pathway which allowed a better understanding of the effects of hyperbilirubinemia on hearing function\(^12\). Although some previous studies argued that the pathology in the auditory tract affects cochlea and/or the 8\(^{th}\) nerve without brainstem involvement; more recently, an auditory disorder characterized by normal cochlear functions (as evidenced by the presence of cochlear microphonics in ABR and the normal OAE response) but unresponsive to treatment or severely impaired ABR has been found related to bilirubin toxicity\(^13-16\). This condition which develops at the retrocochlear (neuronal) level, is now described as auditory neuropathy spectrum disorder (ANSD)\(^4,15,16\). In series of ABRs, it was shown that ANSD findings can be improved and neuronal damage can be reversible after timely applied phototherapy and exchange transfusion. If irreversible neuronal damage develops due to bilirubin toxicity, permanent hearing loss may occur. This suggests that one of the most susceptible regions to neurotoxicity due to hyperbilirubinemia is the auditory pathway\(^15,17,18\). In fact, hearing loss may be the only sign of chronic bilirubin encephalopathy\(^4,16\).

Results of the ABR examinations performed in our study did not reveal any statistically significant difference between the study and the control groups in terms of I, III, V wave latencies and interpeak intervals of I-III, III-V, and I-V waves. However, four patients had hearing loss (9.8%). While no ABR record was obtained in two of our patients with hearing loss (Cases 1 and 5), the presence of cochlear microphonics suggested the presence of ANSD. In Case 1, bilateral normal response was obtained in OAE, but in Case 5, any OAE response could not be elicited. However, it was thought that this finding might be related to his adenoid vegetation and nasal congestion. In the other two cases (Cases 2 and 4), the findings of bilateral hearing loss in ABR and lack of response in OAE test were attributed to cochlear hearing loss. It was thought that the toxicity caused by hyperbilirubinemia in the auditory tract may affect both the 8\(^{th}\) cranial nerve (retrocochlear region) and hearing cells in the cochlea. This result supports the opinion that screening tests only with ABR or OAE should not be sufficient in infants with a history of severe neonatal hyperbilirubinemia and that ABR and OAE should be performed together\(^16\). Therefore, it will be possible to identify the localization of the damage to the auditory tract and to develop correct treatment approaches. Patients with ANSD do not usually benefit from hearing aids. In recent years, good results have been reported in patients undergoing cochlear implantation\(^18\).

In our study, hearing loss rate of 9.8% found in patients with a history of hyperbilirubinemia was significantly higher compared to the hearing loss rate of 0.1-0.6% in the normal population\(^19\). This result emphasizes the importance of ABR screening in newborn with hyperbilirubinemia requiring treatment to detect possible hearing loss at an early stage (especially before 6 months) and to
prevent irreversible language impairment.

Ogün et al.\textsuperscript{20} did not find any correlation between sTB levels and ABR latencies or thresholds in children aged 24-72 months who had neonatal hyperbilirubinemia (term, sTB 20-24 mg/dl, with no hemolysis). In another study conducted with the similar patient group, any correlation between sTB levels and ABR latencies, was not detected. None of the infants had hearing loss, developmental delay or neurological dysfunction\textsuperscript{21}. On the other hand, some other studies reported a positive correlation between bilirubin levels and ABR results\textsuperscript{22-24}. Ozmert et al.\textsuperscript{9} found that the percentage of abnormal ABR was significantly higher in patients with sTB levels above 20 mg/dl, and the rate of neurological sequelae increased with prolonged exposure to sTB levels above 20 mg/dl. DeVries et al.\textsuperscript{25} reported that the longer the duration of hyperbilirubinemia, the higher the risk of sensorineural hearing loss. In another study, any significant relationship was not found between serum bilirubin levels and IQ, sensorineural hearing loss, and significant neurological disorder after 8 years of follow-up of patients with sTB levels of 20 mg/dl. However, a weak relationship between high bilirubin levels and minor neurological dysfunction was found in the same study\textsuperscript{26}. In a study performed by Scheidt et al.\textsuperscript{27} involving 27,270 infants, a strong correlation was found between serum bilirubin level and motor development disorder at 8th and 12th months in infants small for their gestational age with low birth weight. In our study, it was determined that the maximum sTB levels of the patients with pathologic ABR results and neurological dysfunction were significantly higher than the other patients (p<0.01). There was a positive correlation between the increase in sTB levels, pathologic ABR results (r=0.497; p<0.01) and neurological dysfunction (r=0.513; p<0.01). Similarly, the duration of exposure to sTB levels above 20 mg/dl in patients with neurological dysfunction and pathologic ABR results was found to be significantly longer than those without neurological signs and pathologic ABR results (p<0.01).

These findings suggest that not only the increase in bilirubin levels but also the duration of exposure to high bilirubin levels play an important role in increasing the risk of bilirubin neurotoxicity.

Several studies have investigated whether ABR has a predictive value for neurological dysfunction in patients with neonatal hyperbilirubinemia. Kuriyama et al.\textsuperscript{28} found pathological ABR after treatment in two of 30 hyperbilirubinemic infants. Neurological evaluation of these infants for one year revealed cerebral palsy in one, and lack of neurological dysfunction in the other patient. In another study, serial ABR recordings performed at 3-month intervals in newborns with a sTB level >20 mg/dl suggested that persistence of ABR disorders may be a leading symptom of chronic bilirubin encephalopathy\textsuperscript{29}. In the study of Ozmert et al.\textsuperscript{9}, ABR results were pathological in all patients with significant neurological findings, and in 46.6% of those with mild neurological findings. The sensitivity and specificity of ABR were found to be 100% and 81%, respectively in the long-term follow-up of infants with hyperbilirubinemia. In our study, when neurological findings and ABR results were compared, there was a strong relationship between neurological dysfunction and pathological ABR results. However, it should be kept in mind that normal ABR recording can be obtained even in cases with damage to the basal ganglia, since the ABR examination does not provide information on regions above the brainstem. In other words, extrapyramidal findings may develop in patients with normal ABR examination\textsuperscript{4}. Therefore, further studies are needed to establish the predictive value of ABR for persistent neurological dysfunction in patients with neonatal hyperbilirubinemia.

Specific anatomical localization of brain damage caused by kernicterus can be detected with cranial MRI. The characteristic findings on MRI are areas of increased intensity in the globus pallidus, subthalamus and hippocampus. This increase in intensity is bilateral, symmetrical and is more
prominent in T1 sections in the neonatal period, while it is more clearly observed in T2-weighted sections in the advanced stages. On the other hand, cranial MRI can be normal in patients with chronic bilirubin encephalopathy\textsuperscript{4,30}. In our study, in two of the five patients with neurologic findings who underwent cranial MRI examination, increased symmetrical intensity was detected in the T2-weighted section in the basal ganglia (globus pallidus and subthalamic nuclei), whereas MRI imaging was found to be normal in the other three patients.

**Limitations of the Study**

This was a single-centered study performed with limited number of patients

**CONCLUSION**

This study demonstrates that kernicterus may develop in term newborns with severe hyperbilirubinemia (>25 mg/dl) without any finding of significant hemolysis. It has been shown that the risk of developing bilirubin neurotoxicity may increase by not only high bilirubin levels, but also by prolonged exposure to high bilirubin levels. In Turkey, newborn hearing screening test has been implemented since 2004 under the national hearing screening program\textsuperscript{31}. Infants at risk for hearing loss such as hyperbilirubinemia are referred to audiology clinics for advanced audiological tests after screening tests. The high rate of hearing loss in our patients emphasizes the importance of sophisticated hearing tests for the early diagnosis of possible hearing loss in newborns with severe hyperbilirubinemia.

**REFERENCES**

1. Ambalavanan N, Carlo WA. Kernicterus In: Kliegman RM, Stanton BF, St Geme JW, Schor NF (eds). Nelson Textbook of Pediatrics. 20th ed. Philadelphia, PA: Elsevier, 2016:876-80.
2. Maisels MJ, Newman TB. Kernicterus in Otherwise Healthy, Breast-Fed Term Newborns. Pediatrics. 1995;96:730-3.
3. American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. Pediatrics. 2004;114:297-316.
4. Usman F, Diala UM, Shapiro SM, Le Pichon JB, Slusher TM. Acute bilirubin encephalopathy and its progression to kernicterus: current perspectives. Research and Reports in Neonatology. 2018;8:33-44. [CrossRef]
5. Maisels MJ, Bhutani VK, Bogen D, Newman TB, Stark AR, Watchko JF. Hyperbilirubinemia in the Newborn Infant 35 Weeks’ Gestation: An Update With Clarifications. Pediatrics. 2009;124:1193-98. [CrossRef]
6. Coban A, Turkmén M, Gursoy T. Türk Neonatoloji Derneği Yenidoğan Sarılıklarında Yaklaşım, İzlem ve Tedavi Rehberi. Türkiye: 2014. Available at: http://www.neonatology.org.tr/wp-content/uploads/2019/10/Sarılık.pdf
7. Riordan SM, Bittel DC, Le Pichon JB, et al. A hypothesis for using pathway genetic load analysis for understanding complex outcomes in bilirubin encephalopathy. Front Neurosci. 2016;10:376. [CrossRef]
8. Newman TB, Maisels MJ. Evaluation and treatment of jaundice in the term newborn: A kinder gentler approach. Pediatrics. 1992;89:809-18.
9. Ozmert E, Erdem G, Topcu M, et al. Long-term follow-up of indirect hyperbilirubinemia in full-term Turkish infants. Acta Paediatr. 1996;85:1440-4. [CrossRef]
10. Harris MC, Bernbaum JC, Polin JR, Zimmerman R, Polin RA. Developmental follow-up of breastfed term and near-term infants with marked hyperbilirubinemia. Pediatrics. 2001;107:1075-80. [CrossRef]
11. Penn AA, Enzmann DR, Hahn JS, Stevenson DK. Kernicterus in a full term infant. Pediatrics. 1994;93(6 Pt 1):1003-6.
12. Lenhardt ML, McArtor R, Bryant B. Effects of neonatal hyperbilirubinemia on the brainstem electric response. J Pediatr. 1984;104:281-4. [CrossRef]
13. Streletz LJ, Graziani LJ, Branca PA, Desai HJ, Travis SF, Mikaelian DO. Brainstem auditory evoked potentials in full-term and preterm newborns with hyperbilirubinemia and hypoxemia. Neuropediatrics. 1986;17:66-71. [CrossRef]
14. Rhee CK, Park HM, Jang YJ. Audiologic evaluation of neonates with severe hyperbilirubinemia using transiently evoked otoacoustic emissions and auditory brainstem responses. Laryngoscope. 1999;109:2005-8. [CrossRef]
15. Olds C, Oghalal JS. Audiologic impairment associated with bilirubin-induced neurologic damage. Semin Fetal Neonatal Med. 2015;20:42-6. [CrossRef]
16. Saluja S, Agarwal A, Kler N, Sanjiv A. Auditory neuropathy spectrum disorder in late preterm and term infants with severe jaundice Int J Pediatr Otorhinolaryngol. 2010;74:1292-7. [CrossRef]
17. Deliac P, Demarquez JL, Barberot JP, Sandler B, Paty J. Brainstem auditory evoked potentials in icteric fullterm newborns: alterations after Exchange transfusion. Neuropediatrics. 1990;21:115-8. [CrossRef]
18. Shapiro SM, Popelka GR. Auditory impairment in infants at risk for bilirubin-induced neurologic dysfunction. Semin Perinatol. 2011;35:162-70. [CrossRef]
19. Stein LK. Factors influencing the efficacy of universal newborn hearing screening. Pediatr Clin North Am. 1999;46:95-105. [CrossRef]
20. Oğun B, Serbetçiğlu B, Duman N, Ozkan H, Kirkim G. Long-term outcome of neonatal hyperbilirubinemia: subjective and objective audiological measures. Clin Otolaryngol Allied Sci. 2003;28:507-13. [CrossRef]
21. Duman N, Ozkan H, Serbetcioglu B, Ozgun B, Kumral A, Avcı M. Long-term follow-up of otherwise healthy term infants with marked hyperbilirubinaemia: should the limits of exchange transfusion be changed in Turkey? Acta Paediatr. 2004;93:361-7. [CrossRef]

22. Deorari AK, Singh M, Ahuja GK, et al. One year outcome of babies with severe neonatal hyperbilirubinemia and reversible abnormality in brainstem auditory evoked responses. Indian Pediatr. 1994;31:915-21.

23. Gupta AK, Mann SB. Is auditory brainstem response a bilirubin neurotoxicity marker? Am J Otolaryngol. 1998;19:232-6. [CrossRef]

24. Vohr BR, Karp D, O’Dea C, et al. Behavioral changes correlated with brain-stem auditory evoked responses in term infants with moderate hyperbilirubinemia. J Pediatr. 1990;117(2 Pt 1):288-91. [CrossRef]

25. De Vries LS, Lary S, Whitelaw AG, Dubowitz LM. Relationship of serum bilirubin levels and hearing impairment in newborn infants. Early Hum Dev. 1987;15:269-77. [CrossRef]

26. Newman TB, Klebanoff MA. Neonatal hyperbilirubinemia and long-term outcome: another look at the Collaborative Perinatal Project. Pediatrics. 1993;92:651-7.

27. Scheidt PC, Mellitis ED, Hardy JB, Drage JS, Boggs TR. Toxicity to bilirubin in neonates: infant development during first year in relation to maximum neonatal serum bilirubin concentration. J Pediatr. 1977;91:292-7. [CrossRef]

28. Kuriyama M, Konishi Y, Mikawa H. The effect of neonatal hyperbilirubinemia on the auditory brainstem response. Brain Dev. 1986;8:240-5. [CrossRef]

29. Funato M, Terao S, Tamai H, Shimida S. Follow-up study of auditory brainstem responses in hyperbilirubinemic newborns treated with exchange transfusion. Acta Paediatr Jpn. 1996;38:17-21. [CrossRef]

30. Wisnowski JL, Panigrahy A, Painter MJ, Watchko JF. Magnetic resonance imaging of bilirubin encephalopathy: current limitations and future promise. Semin Perinatol. 2014;38:422-8. [CrossRef]

31. Gökçay G, Boran P, Çiprut A, Bağlam T. The current situation in childhood hearing screening in our country and around the world. Çocuk Sağlığı ve Hastalıkları Dergisi. 2014;57:265-73.